Stockreport

Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress [Seeking Alpha]

Inovio Pharmaceuticals, Inc.  (INO) 
NASDAQ:AMEX Investor Relations: ir.inovio.com/investors/default.aspx
PDF INO ended the quarter with $50.8 million in cash, expects a runway into 2Q26, and announced a $25 million public offering to support operations. Key pipeline progress [Read more]